The best ideas happen when the right people work together.
At Curebound, collaboration is everything.
Our funding model engineers collaboration across multiple disciplines and institutions. We provide early phase, follow-on and clinical trial funding to cross-institutional research teams that bring together physician scientists, clinical researchers, and basic-science researchers to work in partnership on a specific challenge in cancer research.
This combination of bringing clinical data to early, basic discovery research is unique to Curebound, and creates collaborations that otherwise would not exist.
Curebound considers applications for all types of cancer research projects and can curate opportunities for individuals to invest in specific areas of research. For philanthropists and organizations looking to direct funding toward exploration of a particular cancer type or treatment area, Curebound’s world class Scientific Advisory Board (SAB) will make discerning investments.
Curebound funds three types of cancer research grants:
• First time seed grants for high-risk, high-reward, collaborative, translational research. Ideas are innovative and in the early phases, where smaller grants of up to $250,000 can make a big impact in advancing research
• Discovery Grants are one-time grants and will be determined by the peer-review process established by Padres Pedal the Cause and implemented by the six beneficiary institutions.
• Larger and potentially multi-year gifts ranging from $250,000 to $1,000,000 that provide follow on funding to Discovery Grants that have met pre-determined goals e.g., demonstrated efficacy and have a clear plan of action e.g., to demonstrate innovation and differentiation with respect to standard-of-care and progress to meaningful clinical milestones, along with a well-supported budget.
• The SAB will also consider targeted funding for major public health and population studies as they align with Curebound investment pillars.
• Innovative, game changing, multidisciplinary projects that receive major funding ranging from $1,000,000 to $5,000,000, administered over multiple years.
• Cure Prize concepts will be determined collectively by the SAB and will seek to foster collaborations with and invoke matching funds from corporate industry partners, private investors, major federal grants and grants from other foundations.
Curebound raises and invests strategic funding in translational cancer research projects aimed at accelerating new discoveries to clinical application. The full index of our research portfolio is available below.
Cancer immunotherapies have led to major treatment breakthroughs for a number of different cancers, but the majority of head and neck cancer patients do not respond to immunotherapies, and clinical responses…Read More
Children with high-risk and recurrent solid tumors have extremely poor outcomes despite aggressive therapy, and new treatments are desperately needed.Read More
Metastatic castration resistant prostate cancer (CRPC) is a lethal disease that claims 30,000 lives annually in the U.S. Although current approved drugs will slow the growth of metastatic CRPC, development of drug resistance—and cancer progression—is inevitable.Read More
Medulloblastoma is the most common malignant brain tumor in children. Although significant advances have been made in treating medulloblastoma, many patients still die from the disease, and those who survive suffer severe long-term side effects from therapy.Read More
Children with aggressive neuroblastoma tumors have poor rates of survival and cure despite intensive treatment, and new therapies are needed. Treatments that block the actions of important proteins and pathways in neuroblastoma tumors are likely to be more effective with fewer side effects...Read More
Pancreatic cancer remains one of the deadliest and most aggressive types of cancer, with a five-year survival rate of 9%. We recently discovered that the levels of two proteins predict survival outcome.Read More
A team of researchers comprised of engineers, cancer biologists, and physician-scientists have joined forces to intercept the devastating disease that is Gastric Cancer (GC).Read More
Pancreatic cancer is a devastating disease with few effective treatments. Moreover, recent immunotherapy approaches that have been remarkably successful in certain cancers have failed in pancreatic cancer. This poor performance of current therapies is in large part due to the presence of a complex cellular support network or stroma that surrounds the tumor.Read More
Acute Myelogenous Leukemia (AML) is a cancer marked by rapid and uncontrolled growth of immature cells of the myeloid lineage. Although it is the most common acute leukemia in adults, current treatments, which include chemotherapy and bone marrow transplantation, are largely ineffective, leading to relapse and death in most patients.Read More